Harbor Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Harbor Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$912K	Buy	+15,944	New	+$873K	0.06%	384
2025 Q1	–	Sell	-3,851	Closed	-$253K	–	1423
2024 Q4	$253K	Buy	3,851 +93	+2%	+$6.23K	0.01%	632
2024 Q3	$264K	Buy	3,758 +15	+0.4%	+$1.25K	0.01%	643
2024 Q2	$308K	Buy	3,743 +11	+0.3%	+$916	0.02%	605
2024 Q1	$326K	Buy	3,732 +373	+11%	+$33.4K	0.04%	502
2023 Q4	$324K	Buy	3,359 +1	+0%	+$88	0.06%	306
2023 Q3	$297K	Hold	3,358	–	–	0.06%	308
2023 Q2	$291K	Hold	3,358	–	–	0.06%	323
2023 Q1	$327K	Buy	+3,358	New	+$348K	0.09%	177

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Harbor Capital Advisors's BMRN Position: Q2 2026 in Review

Harbor Capital Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 15,944 shares worth $912K. The stake represents 0.06% of the portfolio and ranks #384 among its holdings. This is a return to the name: Harbor Capital Advisors previously reported a position in BMRN as recently as Q4 2024.

Harbor Capital Advisors first reported a position in BMRN in Q1 2023 and has held it in 9 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Harbor Capital Advisors held 15,944 shares of BioMarin Pharmaceuticals worth $912K as of Q2 2026.
BioMarin Pharmaceuticals was a new Harbor Capital Advisors position in Q2 2026.
BioMarin Pharmaceuticals made up 0.06% of Harbor Capital Advisors's portfolio in Q2 2026, its #384 holding.
Harbor Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2023 and has held it in 9 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.